CING vs. KZIA, CPHI, KTRA, NEXI, DRUG, SNPX, TFFP, RNAZ, ARTL, and GTBP
Should you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Kazia Therapeutics (KZIA), China Pharma (CPHI), Kintara Therapeutics (KTRA), NexImmune (NEXI), Bright Minds Biosciences (DRUG), Synaptogenix (SNPX), TFF Pharmaceuticals (TFFP), TransCode Therapeutics (RNAZ), Artelo Biosciences (ARTL), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical preparations" industry.
Kazia Therapeutics (NASDAQ:KZIA) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.
In the previous week, Cingulate had 1 more articles in the media than Kazia Therapeutics. MarketBeat recorded 1 mentions for Cingulate and 0 mentions for Kazia Therapeutics. Cingulate's average media sentiment score of 0.00 beat Kazia Therapeutics' score of -0.43 indicating that Kazia Therapeutics is being referred to more favorably in the media.
30.9% of Kazia Therapeutics shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 1.0% of Kazia Therapeutics shares are held by insiders. Comparatively, 21.8% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Kazia Therapeutics has higher revenue and earnings than Cingulate.
Cingulate has a consensus target price of $8.00, indicating a potential upside of 912.79%. Given Kazia Therapeutics' higher possible upside, analysts plainly believe Cingulate is more favorable than Kazia Therapeutics.
Kazia Therapeutics received 72 more outperform votes than Cingulate when rated by MarketBeat users. However, 66.67% of users gave Cingulate an outperform vote while only 52.35% of users gave Kazia Therapeutics an outperform vote.
Kazia Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.87, suggesting that its stock price is 187% less volatile than the S&P 500.
Summary
Kazia Therapeutics and Cingulate tied by winning 6 of the 12 factors compared between the two stocks.
Get Cingulate News Delivered to You Automatically
Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cingulate Competitors List
Related Companies and Tools
